Search
Zapomeran
go.drugbank.com/drugs/DB21761Approved[L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585] … [L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell.
Diazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A190372] Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. … [A190372] When administered intravenously, diazoxide can be used to treat hypertensive emergencies;[L44622] however, this specific form of diazoxide is no longer available in the US.
Ataluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnIt has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases.
Methotrimeprazine
go.drugbank.com/drugs/DB01403ApprovedIt has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCorynebacterium diphtheriae
go.drugbank.com/drugs/DB09877ApprovedInvestigationalThe vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children. … *Corynebacterium diphtheriae* toxin is extracted from the pathogenic actinobacterium *C. diphtheriae* that causes diphtheria.
Mixtures: Td-pur für Erwachsene und HeranwachsendePhysostigmine
go.drugbank.com/drugs/DB00981ApprovedIt can be applied topically to the conjunctiva. … It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedD2 receptors have been the most common target for antipsychotic agents used in the treatment of schizophrenia: the positive symptoms are thought to arise from overactivity in the mesolimbic dopaminergic … Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity to the cognate ligands than the endogenous individual receptor. … [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment
Imipramine
go.drugbank.com/drugs/DB00458ApprovedInvestigationalImipramine may be used to treat depression and nocturnal enuresis in children [FDA Label]. … Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: SICOTONE - IFSA TABLETA DE 25 MG.